17beta-Estradiol, Selective agonist of ER receptor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Estrogen Receptor (ER) also known by its alternate names NR3A1 (nuclear receptor subfamily 3 group A member 1) is a nuclear hormone receptor that binds estrogens such as the 17 beta estradiol molecule. Its molecular mass is approximately 66 kDa. This receptor locates mainly in the cytoplasm and nucleus of cells within tissues such as the breast uterus and bone. The ER exists in two primary subtypes ER alpha and ER beta which differ in their tissue distribution and functional roles.

Biological function summary

The Estrogen Receptor functions as a transcription factor that regulates gene expression when it binds to its ligand which is commonly estradiol. Upon binding 17 beta estradiol the receptor dimerizes and interacts with specific DNA sequences to influence transcription. It significantly regulates genes responsible for cell growth differentiation and reproductive functions. The estradiol chemical structure allows for specific interactions with ER altering the transcriptional regulation in a ligand-dependent manner. Though functioning mainly as a monomer ER can form heterodimers with other nuclear receptors affecting its biological role.

Pathways

The Estrogen Receptor is an important player in the genomic signaling pathway where it modulates the expression of numerous target genes by direct DNA binding. It also participates in the non-genomic signaling pathway where it involves the activation of second messengers and kinases. ER closely associates with important proteins such as coactivators and corepressors in these pathways. Estradiol chemical formula interactions facilitate molecular events involving ER-alpha to influence components of cell proliferation and survival.

The Estrogen Receptor is intricately linked to breast cancer and osteoporosis. Dysfunction in ER signaling promotes the proliferation of breast cancer cells often requiring targeted therapies that inhibit its action. In osteoporosis ER activity impacts bone density and turnover through regulation of osteoclasts and osteoblasts. The receptor's interaction with growth factor receptors like HER2 in breast cancer further highlights its significance in disease pathogenesis.